IFNAR Inhibitors

The Interferon-alpha/beta receptor (IFNAR) is a heterodimeric cell surface receptor complex composed of two subunits, IFNAR1 and IFNAR2, that serves as the primary transducer for Type I interferons (IFN-α, IFN-β, IFN-ω, IFN-κ, IFN-τ). Upon binding of Type I IFNs, IFNAR activates the Janus kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) signaling pathway. This activation leads to the phosphorylation of JAK1 and Tyk2 (associated with IFNAR1 and IFNAR2, respectively), which in turn phosphorylate STAT1 and STAT2. Phosphorylated STATs then dimerize, translocate to the nucleus, and, in complex with IRF9, bind to interferon-stimulated response elements (ISREs) in the promoters of target genes, leading to the transcription of hundreds of interferon-stimulated genes (ISGs). This pathway is fundamental to the body's antiviral defense, immune modulation, and anti-proliferative responses. Dysregulated or excessive Type I IFN signaling is a central driver in the pathogenesis of several autoimmune diseases.

Systemic lupus erythematosus (SLE) is the most prominent example, where a persistent Type I IFN signature correlates with disease activity and severity. Other conditions linked to aberrant IFNAR signaling include Sjogren's syndrome, dermatomyositis, and systemic sclerosis. In certain cancers, while Type I IFNs can have anti-tumor effects, chronic or dysregulated signaling can paradoxically promote tumor growth or immune evasion. Current research on IFNAR inhibitors has yielded significant clinical success, particularly in autoimmune diseases. Anifrolumab (Saphnelo), a human monoclonal antibody that specifically binds to the IFNAR1 subunit, thereby blocking the activity of all Type I IFNs, is approved for the treatment of adult patients with moderate to severe active SLE. This approval represents a major advancement in targeting the Type I IFN pathway.

Other anti-IFNAR antibodies and small molecule inhibitors targeting downstream JAKs (e.g., baricitinib, tofacitinib) are also in various stages of clinical development for a range of autoimmune and inflammatory conditions. Inhibitors can be broadly classified as monoclonal antibodies (targeting either IFNAR1 or IFNAR2 to block ligand binding), soluble decoy receptors, or small molecules that inhibit downstream signaling components like JAKs. A key challenge in IFNAR inhibition is balancing immune suppression to treat autoimmune disease with maintaining sufficient antiviral immunity, as Type I IFNs are crucial for host defense against viral infections. Patients undergoing IFNAR blockade may have an increased risk of certain infections. The use of biomarkers, such as the Type I IFN gene signature, is critical for identifying patients most likely to respond to IFNAR-targeted therapies. Combination therapies with other immunosuppressants or disease-modifying antirheumatic drugs (DMARDs) are also being explored to optimize treatment outcomes.

Vadimezan (DMXAA) targeted cGAS-STING signaling regulation and hepatocyte apoptotic responses
Vadimezan (DMXAA) targeted cGAS-STING signaling regulation and hepatocyte apoptotic responses